Pharmaceutics (Oct 2023)

Design, Development, Evaluation, and In Vivo Performance of Buccal Films Embedded with Paliperidone-Loaded Nanostructured Lipid Carriers

  • Fahad Mohammed AlMulhim,
  • Anroop B. Nair,
  • Bandar Aldhubiab,
  • Hiral Shah,
  • Jigar Shah,
  • Vivek Mewada,
  • Nagaraja Sreeharsha,
  • Shery Jacob

DOI
https://doi.org/10.3390/pharmaceutics15112530
Journal volume & issue
Vol. 15, no. 11
p. 2530

Abstract

Read online

The therapeutic effectiveness of paliperidone in the treatment of schizophrenia has been limited by its poor oral bioavailability; hence, an alternative route could be appropriate. This study investigates the feasibility of developing a buccal film impregnated with paliperidone-loaded nanostructured lipid carriers (NLCs) and assesses the potential to enhance its bioavailability. Box–Behnken-based design optimization of NLCs was performed by examining the particles’ physical characteristics. The polymeric film was used to load optimized NLCs, which were then assessed for their pharmaceutical properties, permeability, and pharmacokinetics. The optimization outcomes indicated that selected formulation variables had a considerable (p p p 0–12 (p < 0.0001) and greater relative bioavailability (236%) than the control. These results support the conclusion that paliperidone-loaded NLC buccal film has the potential to be an alternate therapy for its effective administration in the treatment of schizophrenia.

Keywords